Chengdu HUITAI Biomedicine is a clinical-stage biotech company focused on developing pan anti-fibrotic peptides through novel TGF-β technology. Our lead asset, inhaled peptide HTPEP-001 for IPF and PF-ILD, decreases the activation of TGF-β via a CD36 derived peptide and is ready to enter phase II clinical trial. We have other pipelines targeting fibrosis of other organs like liver, kidney, intestine, etc. We are looking for investment and BD opportunities.